 |
 |
 |
On February 1, 2008, Genentech launched an exciting new program designed to
improve patient access to Pulmozyme® (dornase alfa Inhalation Solution):
Pulmozyme® Access Solutions™.
The Pulmozyme Access Solutions team at Genentech
is available to provide the following services for people with cystic fibrosis:
- A Reimbursement Assistance
Hotline
- Thorough Benefits Investigations and
Prior Authorization Assistance
- A Dedicated Pulmozyme Access Solutions Case
Manager
- Appeals Assistance for Coverage
Denials
- An Alternative Funding Specialist for Referrals to
Co-pay Assistance Organizations
- The Genentech® Access to Care
Foundation for qualifying uninsured or under-insured patients
- The Pulmozyme StarteRx Program for
first-time users of Pulmozyme
- Information Resources via www.PulmozymeAccessSolutions.com
In conjunction with the launch of Pulmozyme Access
Solutions, the Genentech Endowment for Cystic Fibrosis stopped accepting
new patients on February 1, 2008 and will end operations on March 31,
2008.
If you are interested in learning more about or enrolling in Pulmozyme Access
Solutions, please call the Pulmozyme Access Solutions team at 1-800-690-3023,
Monday through Friday, 6 a.m. to 5 p.m. PST, or visit www.PulmozymeAccessSolutions.com.
For well over a decade, the Genentech Endowment for Cystic Fibrosis has
provided assistance to many people with CF who have been prescribed Pulmozyme.
We are proud of the services we have provided, the high standards we set, and
our commitment to patients. With Pulmozyme Access Solutions, we are expanding
our commitment to patients, and we will continue to seek out new and better ways
to solve issues related to coverage and reimbursement until access ceases to be
a problem for any of the patients we serve.
|
 |
|
 |